Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis

J Neurol Neurosurg Psychiatry. 1996 Mar;60(3):348-9. doi: 10.1136/jnnp.60.3.348-a.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Chronic Disease
  • Genetic Predisposition to Disease
  • Hepatitis C / therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Myasthenia Gravis / chemically induced*
  • Myasthenia Gravis / genetics
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins